› 6c9n

X-ray diffraction
2.1Å resolution

Mycobacterium tuberculosis adenosine kinase bound to sangivamycin

Released:
DOI: 10.2210/pdb6c9n/pdb
Model geometry
Fit model/data
PDB entry 6c9n coloured by chain, front view.
PDB entry 6c9n coloured by chain, side view.
PDB entry 6c9n coloured by chain, top view.
Source organism: Mycobacterium tuberculosis
Primary publication:
Structure-Guided Drug Design of 6-Substituted Adenosine Analogues as Potent Inhibitors of Mycobacterium tuberculosis Adenosine Kinase.
Crespo RA, Dang Q, Zhou NE, Guthrie LM, Snavely TC, Dong W, Loesch KA, Suzuki T, You L, Wang W, O'Malley T, Parish T, Olsen DB, Sacchettini JC
OpenAccess logo J Med Chem 62 4483-4499 (2019)
PMID: 31002508

Function and Biology Details

Reaction catalysed: 
ATP + adenosine = ADP + AMP
Biochemical function:
Biological process:
Cellular component:
Sequence domains:

Structure analysis Details

Assembly composition:
homo dimer (preferred)
Assembly name:
PDBe Complex ID:
PDB-CPX-161618 (preferred)
Entry contents:
1 distinct polypeptide molecule
Macromolecule:
Adenosine kinase Chains: A, B
Molecule details ›
Chains: A, B
Length: 324 amino acids
Theoretical weight: 34.5 KDa
Source organism: Mycobacterium tuberculosis
Expression system: Escherichia coli
UniProt:
  • Canonical: P9WID5 (Residues: 1-324; Coverage: 100%)
Gene names: MTCY190.13c, Rv2202c, adoK, cbhK
Sequence domains: pfkB family carbohydrate kinase
Structure domains: UDP-N-acetylmuramoyl-L-alanine:D-glutamate ligase

Ligands and Environments

4 bound ligands:
Ligand SGV 4 x SGV
Ligand GOL 1 x GOL
Ligand SO4 2 x SO4
Ligand NA 2 x NA
No modified residues

Experiments and Validation Details

wwPDB Validation report is not available for this entry.
X-ray source: APS BEAMLINE 19-ID
Spacegroup: P41
Unit cell:
a: 48.91Å b: 48.91Å c: 262.059Å
α: 90° β: 90° γ: 90°
R-values:
R R work R free
0.189 0.187 0.231
Expression system: Escherichia coli

Quick links

Citations

1 review citation

Biosynthesis of Galactan in Mycobacterium tuberculosis as a Viable TB Drug Target?
Konyariková et al. (2020)
2 other articles

2 mentions without citation

An Outline of the Latest Crystallographic Studies on Inhibitor-Enzyme Complexes for the Design and Development of New Therapeutics against Tuberculosis.
Mori et al. (2021)
1 more

PDB-REDO

The sliders below show the change in model quality between original PDB entry and the PDB-REDO entry

Model Geometry
 
 
Data not available
DNA/RNA Geometry
 
 
Data not available
Fit model/data
 
 
Data not available
PDB-REDO